Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Verve Therapeutics (VERV), a clinical-stage biotechnology company focused on developing genetic medicines for cardiovascular disease, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Dr. Sekar Kathiresan, the company's co-founder and CEO, will deliver a presentation on Wednesday, January 15, 2025, at 11:15 a.m. PT in San Francisco.
The presentation will be accessible through a live webcast on the investor section of Verve's website at www.vervetx.com. Interested parties can access the archived version of the webcast for 30 days following the presentation.
Verve Therapeutics (VERV), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di terapie genetiche per malattie cardiovascolari, ha annunciato la sua partecipazione alla 43a Conferenza Annuale J.P. Morgan Healthcare. Il Dr. Sekar Kathiresan, co-fondatore e CEO dell'azienda, farà una presentazione mercoledì 15 gennaio 2025, alle 11:15 ora pacifica a San Francisco.
La presentazione sarà accessibile tramite una diretta streaming nella sezione dedicata agli investitori del sito web di Verve all'indirizzo www.vervetx.com. Le parti interessate potranno accedere alla versione archiviata della diretta per 30 giorni dopo la presentazione.
Verve Therapeutics (VERV), una compañía de biotecnología en etapa clínica enfocada en desarrollar tratamientos genéticos para enfermedades cardiovasculares, ha anunciado su participación en la 43ª Conferencia Anual de J.P. Morgan Healthcare. El Dr. Sekar Kathiresan, cofundador y CEO de la compañía, realizará una presentación el miércoles 15 de enero de 2025, a las 11:15 a.m. PT en San Francisco.
La presentación será accesible a través de una transmisión en vivo en la sección para inversores del sitio web de Verve en www.vervetx.com. Las partes interesadas podrán acceder a la versión archivada de la transmisión durante 30 días después de la presentación.
Verve Therapeutics (VERV)는 심혈관 질환을 위한 유전자 치료제를 개발하는 임상 단계의 생명공학 회사로, 제43회 J.P. Morgan Healthcare 컨퍼런스에 참여할 것이라고 발표했습니다. 세카르 카티레산 박사는 이 회사의 공동 설립자이자 CEO로서 2025년 1월 15일 수요일 오전 11시 15분 PT에 샌프란시스코에서 발표를 진행할 예정입니다.
발표는 Verve 웹사이트의 투자자 섹션에서 라이브 웹캐스트를 통해 시청할 수 있습니다(www.vervetx.com). 관심 있는 분들은 발표 후 30일간 웹캐스트의 아카이브 버전을 이용할 수 있습니다.
Verve Therapeutics (VERV), une entreprise de biotechnologie en phase clinique spécialisée dans le développement de médicaments génétiques pour les maladies cardiovasculaires, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare. Dr. Sekar Kathiresan, co-fondateur et PDG de l'entreprise, présentera une conférence le mercredi 15 janvier 2025, à 11h15 PT à San Francisco.
La présentation sera accessible via un webinaire en direct dans la section investisseurs du site web de Verve à l'adresse www.vervetx.com. Les parties intéressées pourront accéder à la version archivée du webinaire pendant 30 jours après la présentation.
Verve Therapeutics (VERV), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung genetischer Therapien für Herz-Kreislauf-Erkrankungen spezialisiert hat, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz bekannt gegeben. Dr. Sekar Kathiresan, Mitbegründer und CEO des Unternehmens, wird am Mittwoch, den 15. Januar 2025, um 11:15 Uhr PT in San Francisco eine Präsentation halten.
Die Präsentation wird über einen Live-Stream im Investorenbereich der Verve-Website unter www.vervetx.com zugänglich sein. Interessierte Parteien können die archivierte Version des Webcasts 30 Tage nach der Präsentation abrufen.
- None.
- None.
BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 11:15 a.m. PT in San Francisco.
A live webcast will be available in the investor section of the company’s website at www.vervetx.com. The webcast will be archived for 30 days following the presentation.
About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic management to single-course gene editing medicines. The company’s lead programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established ASCVD who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia (HoFH). For more information, please visit www.VerveTx.com.
Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com
Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
FAQ
When is Verve Therapeutics (VERV) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors access VERV's J.P. Morgan Healthcare Conference presentation?
How long will VERV's J.P. Morgan Conference presentation be available for replay?
What type of medicines is Verve Therapeutics (VERV) developing?
Who will be presenting for Verve Therapeutics (VERV) at the J.P. Morgan Healthcare Conference?
